MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1210/jc.2012-1205

Медицинская библиотека · The Journal of clinical endocrinology and metabolism · 2012

Mechanisms for the antihyperglycemic effect of sitagliptin in patients with type 2 diabetes.

Muscelli Elza, Casolaro Arturo, Gastaldelli Amalia, Mari Andrea, Seghieri Giuseppe, Astiarraga Brenno, Chen Yu, Alba Maria, Holst Jens, Ferrannini Ele

СтатьяРандомизированное исследованиеПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

CONTEXT: Dipeptidyl peptidase IV (DPP-4) inhibitors improve glycemic control in patients with type 2 diabetes. The underlying mechanisms (incretin effect, β-cell function, endogenous glucose production) are not well known.

OBJECTIVE

The aim of the study was to examine mechanisms of the antihyperglycemic effect of DPP-4 inhibitors.

DESIGN, SETTING, AND PATIENTS: We administered a mixed meal with glucose tracers ([6,6-(2)H(2)]-glucose infused, [1-(2)H]-glucose ingested), and on a separate day, a glucose infusion matched the glucose responses to the meal (isoglycemic test) in 50 type 2 diabetes patients (hemoglobin A(1c) = 7.4 ± 0.8%) and seven controls; 47 diabetic completers were restudied after 6 wk. Glucose fluxes were calculated, and β-cell function was assessed by mathematical modeling. The incretin effect was calculated as the ratio of oral to iv insulin secretion.

INTERVENTION: We conducted a 6-wk, double-blind, randomized treatment with sitagliptin (100 mg/d; n = 25) or placebo (n = 22).

RESULTS

Relative to placebo, meal-induced changes in fasting glucose and glucose area under the curve (AUC) were greater with sitagliptin, in parallel with a lower appearance of oral glucose [difference (post-pre) AUC = -353 ± 915 vs. +146 ± 601 μmol · kg(-1) · 5 h] and greater suppression of endogenous glucose production. Insulin sensitivity improved 10%, whereas total insulin secretion was unchanged. During the meal, β-cell glucose sensitivity improved (+19[29] vs. 5[21] pmol · min(-1) · m(-2) · mm(-1); median [interquartile range]) and glucagon AUC decreased (19.6 ± 7.5 to 17.3 ± 7.1 ng · ml(-1) · 5 h), whereas intact glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 AUC increased with sitagliptin vs. placebo. The incretin effect was unchanged because sitagliptin increased β-cell glucose sensitivity also during the isoglycemic test.

CONCLUSIONS

Chronic sitagliptin treatment improves glycemic control by lowering the appearance of oral glucose, postprandial endogenous glucose release, and glucagon response, and by improving insulin sensitivity and β-cell glucose sensing in response to both oral and iv glucose.

Для цитирования: Muscelli Elza, Casolaro Arturo, Gastaldelli Amalia, Mari Andrea, Seghieri Giuseppe, Astiarraga Brenno, Chen Yu, Alba Maria, Holst Jens, Ferrannini Ele. Mechanisms for the antihyperglycemic effect of sitagliptin in patients with type 2 diabetes.. The Journal of clinical endocrinology and metabolism. 2012. DOI: 10.1210/jc.2012-1205.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.